Systemic JIA: new developments in the understanding of the pathophysiology and therapy.

[1]  A. Ramanan,et al.  Review of haemophagocytic lymphohistiocytosis , 2010, Archives of Disease in Childhood.

[2]  Lukasz Itert,et al.  Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.

[3]  R. Russo,et al.  Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents , 2009, The Journal of Rheumatology.

[4]  C. Tremblay,et al.  Potential Role of Interleukin-18 in the Immunopathogenesis of AIDS: Involvement in Fratricidal Killing of NK Cells , 2009, Journal of Virology.

[5]  T. Miyamae,et al.  The role of heme oxygenase-1 in systemic-onset juvenile idiopathic arthritis , 2009, Modern rheumatology.

[6]  D. Foell,et al.  The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. , 2009, Arthritis and rheumatism.

[7]  D. Foell,et al.  S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. , 2008, Arthritis and rheumatism.

[8]  D. Glass,et al.  Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. , 2008, Arthritis and rheumatism.

[9]  D. Kastner,et al.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. , 2008, Arthritis and rheumatism.

[10]  A. Reiff,et al.  Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[11]  A. Martini,et al.  The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[12]  T. Kishimoto,et al.  Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.

[13]  N. Wulffraat,et al.  Current perspectives of autologous stem cell transplantation for severe juvenile idiopathic arthritis , 2008, Autoimmunity.

[14]  J. Roth,et al.  New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment. , 2007, Rheumatology.

[15]  P. Woo.  Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease , 2007, Annals of the rheumatic diseases.

[16]  J. Sibilia,et al.  Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.

[17]  G. Cook,et al.  Primer: inflammasomes and interleukin 1β in inflammatory disorders , 2008, Nature Clinical Practice Rheumatology.

[18]  Sherry Thornton,et al.  Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. , 2007, Arthritis and rheumatism.

[19]  V. Pascual,et al.  Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade , 2007, The Journal of experimental medicine.

[20]  W. Nacken,et al.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock , 2007, Nature Medicine.

[21]  Paul Kellam,et al.  Specific gene expression profiles in systemic juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[22]  R. Cron,et al.  Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. , 2007, The Journal of rheumatology.

[23]  A. Ramanan,et al.  The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. , 2007, Arthritis and rheumatism.

[24]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[25]  E. Hoppenreijs,et al.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study , 2006, Annals of the rheumatic diseases.

[26]  Mark J. Smyth,et al.  Perforin-mediated target-cell death and immune homeostasis , 2006, Nature Reviews Immunology.

[27]  R. Schneider,et al.  Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. , 2006, The Journal of pediatrics.

[28]  Patricia Woo,et al.  Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome , 2006, Nature Clinical Practice Rheumatology.

[29]  D. Dormont,et al.  Macrophage activation switching: an asset for the resolution of inflammation , 2005, Clinical and experimental immunology.

[30]  A. Ramanan,et al.  Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? , 2005, Rheumatology.

[31]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[32]  A. Reiff,et al.  Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. , 2005, The Journal of rheumatology.

[33]  H. Hennies,et al.  Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. , 2005, Human molecular genetics.

[34]  M. Kurrer,et al.  Soluble hemoglobin–haptoglobin scavenger receptor CD163 as a lineage‐specific marker in the reactive hemophagocytic syndrome , 2005, European journal of haematology.

[35]  I. Foeldvari,et al.  The German etanercept registry for treatment of juvenile idiopathic arthritis , 2004, Annals of the rheumatic diseases.

[36]  R. Sundel,et al.  Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. , 2004, The Journal of pediatrics.

[37]  J. Verbsky,et al.  Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. , 2004, The Journal of rheumatology.

[38]  Sampath Prahalad,et al.  A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. , 2004, Arthritis and rheumatism.

[39]  C. Dinarello.  Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. , 2004, Current opinion in pharmacology.

[40]  B. Beutler,et al.  Inferences, questions and possibilities in Toll-like receptor signalling , 2004, Nature.

[41]  H. Oda,et al.  Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. , 2004, Arthritis and rheumatism.

[42]  A. Grom.  Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? , 2004, Arthritis and rheumatism.

[43]  R. Schneider,et al.  Macrophage activation syndrome--what's in a name! , 2003, The Journal of rheumatology.

[44]  A. Fischer,et al.  Munc13-4 Is Essential for Cytolytic Granules Fusion and Is Mutated in a Form of Familial Hemophagocytic Lymphohistiocytosis (FHL3) , 2003, Cell.

[45]  S. Fisher,et al.  The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. , 2003, Arthritis and rheumatism.

[46]  W. Thomson,et al.  Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. , 2003, Arthritis and rheumatism.

[47]  A. Prieur,et al.  Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. , 2003, Arthritis and rheumatism.

[48]  E. Goldmuntz,et al.  Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. , 2003, The Journal of pediatrics.

[49]  N. Wulffraat,et al.  Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. , 2003, Rheumatology.

[50]  D. Kastner,et al.  The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations , 2003, Current opinion in rheumatology.

[51]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[52]  B. Athreya.  Is macrophage activation syndrome a new entity? , 2002, Clinical and experimental rheumatology.

[53]  S. Moestrup,et al.  Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. , 2002, Blood.

[54]  T. Alonzi,et al.  Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. , 2001, Endocrinology.

[55]  S. Moestrup,et al.  Identification of the haemoglobin scavenger receptor , 2001, Nature.

[56]  W. Thomson,et al.  A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. , 2001, Arthritis and rheumatism.

[57]  C. Doré,et al.  Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. , 2000, Arthritis and rheumatism.

[58]  G. de Saint Basile,et al.  Perforin: more than just an effector molecule. , 2000, Immunology today.

[59]  A. Fischer,et al.  Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome , 2000, Nature Genetics.

[60]  A. Fischer,et al.  Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.

[61]  T. Sasazuki,et al.  Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNFalpha gene and HLA genes. , 1999, Arthritis and rheumatism.

[62]  Jack R. Davis,et al.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene , 1998, Nature Genetics.

[63]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[64]  R. Schneider,et al.  6 Systemic onset juvenile rheumatoid arthritis , 1998 .

[65]  A. Martini,et al.  Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? , 1998, The Journal of rheumatology.

[66]  R. Schneider,et al.  Systemic onset juvenile rheumatoid arthritis. , 1998, Bailliere's clinical rheumatology.

[67]  D. Sherry,et al.  Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. , 1997, Arthritis and rheumatism.

[68]  M. Lovett,et al.  Identification of the homologous beige and Chediak–Higashi syndrome genes , 1996, Nature.

[69]  M. Cazzola,et al.  Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. , 1996, Blood.

[70]  R. Schneider,et al.  Radiologic features of systemic onset juvenile rheumatoid arthritis. , 1995, The Journal of rheumatology.

[71]  D. Glass,et al.  Juvenile rheumatoid arthritis and HLA: report of the Park City III workshop. , 1992, The Journal of rheumatology. Supplement.

[72]  A. Martini,et al.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[73]  A. Prieur,et al.  Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. , 1991, Clinical and experimental rheumatology.

[74]  A. Craft,et al.  Low-dose methotrexate in systemic onset juvenile chronic arthritis. , 1989, Clinical and experimental rheumatology.

[75]  C. Griscelli,et al.  SPECIFIC INTERLEUKIN-1 INHIBITOR IN SERUM AND URINE OF CHILDREN WITH SYSTEMIC JUVENILE CHRONIC ARTHRITIS , 1987, The Lancet.

[76]  C. Griscelli,et al.  Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. , 1985, The Journal of pediatrics.

[77]  M ROBURN,et al.  Femoral neck fractures. , 1964, Lancet.

[78]  G. Still.  On a form of chronic joint disease in children , 1941, Archives of disease in childhood.